(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of 15.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Eyepoint Pharmaceuticals's revenue in 2025 is $56,042,000.On average, 4 Wall Street analysts forecast EYPT's revenue for 2025 to be $2,223,995,308, with the lowest EYPT revenue forecast at $2,049,901,615, and the highest EYPT revenue forecast at $2,559,796,579. On average, 3 Wall Street analysts forecast EYPT's revenue for 2026 to be $169,689,741, with the lowest EYPT revenue forecast at $68,811,736, and the highest EYPT revenue forecast at $261,484,597.
In 2027, EYPT is forecast to generate $8,344,111,107 in revenue, with the lowest revenue forecast at $3,708,952,570 and the highest revenue forecast at $12,979,269,644.